Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 1
1974 1
1975 3
1976 3
1977 3
1979 1
1980 5
1981 6
1982 3
1983 1
1984 4
1985 4
1986 2
1987 3
1988 2
1989 2
1991 2
1992 1
1993 1
1994 2
1995 2
1997 2
1999 1
2001 1
2003 2
2004 2
2005 3
2006 2
2007 10
2008 3
2009 4
2011 7
2012 6
2013 4
2014 5
2015 14
2016 5
2017 5
2018 12
2019 8
2020 4
2021 9
2022 4
2023 13
2024 10
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Datoo MS, Dicko A, Tinto H, Ouédraogo JB, Hamaluba M, Olotu A, Beaumont E, Ramos Lopez F, Natama HM, Weston S, Chemba M, Compaore YD, Issiaka D, Salou D, Some AM, Omenda S, Lawrie A, Bejon P, Rao H, Chandramohan D, Roberts R, Bharati S, Stockdale L, Gairola S, Greenwood BM, Ewer KJ, Bradley J, Kulkarni PS, Shaligram U, Hill AVS; R21/Matrix-M Phase 3 Trial Group. Datoo MS, et al. Among authors: kulkarni ps. Lancet. 2024 Feb 10;403(10426):533-544. doi: 10.1016/S0140-6736(23)02511-4. Epub 2024 Feb 1. Lancet. 2024. PMID: 38310910 Free article. Clinical Trial.
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.
Diallo F, Haidara FC, Tapia MD, Dominguez Islas CP, Alderson MR, Hausdorff WP, Martellet L, Hosken N, Kapse D, Kulkarni PS, Townsend-Payne K, Vanni F, Posavad CM, Sow SO, Kotloff KL, Chen WH; NmCV-5 EPI study team. Diallo F, et al. Among authors: kulkarni ps. Lancet. 2025 Mar 29;405(10484):1069-1080. doi: 10.1016/S0140-6736(25)00046-7. Epub 2025 Mar 11. Lancet. 2025. PMID: 40086461 Clinical Trial.
Proceedings of the dengue endgame summit: Imagining a world with dengue control.
Wegman AD, Kalimuddin S, Marques ETA, Adams LE, Rothman AL, Gromowski GD, Wang TT, Weiskopf D, Hibberd ML, Alex Perkins T, Christofferson RC, Gunale B, Kulkarni PS, Rosas A, Macareo L, Yacoub S, Eong Ooi E, Paz-Bailey G, Thomas SJ, Waickman AT. Wegman AD, et al. Among authors: kulkarni ps. Vaccine. 2024 Oct 3;42(23):126071. doi: 10.1016/j.vaccine.2024.06.038. Epub 2024 Jun 17. Vaccine. 2024. PMID: 38890105
Expert review on global real-world vaccine effectiveness against SARS-CoV-2.
Chuenkitmongkol S, Solante R, Burhan E, Chariyalertsak S, Chiu NC, Do-Van D, Husin M, Hwang KP, Kiertiburanakul S, Kulkarni PS, Lee PI, Lobo RC, Nghia CH, Ong-Lim A, Sivasampu S, Suah JL, Tok PSK, Thwaites G; SEA Vaccine Effectiveness Expert Working Group. Chuenkitmongkol S, et al. Among authors: kulkarni ps. Expert Rev Vaccines. 2022 Sep;21(9):1255-1268. doi: 10.1080/14760584.2022.2092472. Epub 2022 Jun 30. Expert Rev Vaccines. 2022. PMID: 35748494 Free article. Review.
Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia.
Haidara FC, Umesi A, Sow SO, Ochoge M, Diallo F, Imam A, Traore Y, Affleck L, Doumbia MF, Daffeh B, Kodio M, Wariri O, Traoré A, Jallow E, Kampmann B, Kapse D, Kulkarni PS, Mallya A, Goel S, Sharma P, Sarma AD, Avalaskar N, LaForce FM, Alderson MR, Naficy A, Lamola S, Tang Y, Martellet L, Hosken N, Simeonidis E, Welsch JA, Tapia MD, Clarke E. Haidara FC, et al. Among authors: kulkarni ps. N Engl J Med. 2023 May 25;388(21):1942-1955. doi: 10.1056/NEJMoa2214924. N Engl J Med. 2023. PMID: 37224196 Free PMC article. Clinical Trial.
Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial.
Kulkarni PS, Potey AV, Kapse D, Bhamare C, Gawande A, Munshi R, Pawar S, Gogtay NJ, Agarwal A, Tambe M, Thakre S, Samuel CJ, Khan SMS, S RH, Rana D, Singh N, Kamath V, Bhalla HL, Poonawalla CS, Mani RS, Gunale B; RAB-04 study group. Kulkarni PS, et al. Lancet. 2025 Aug 9;406(10503):627-635. doi: 10.1016/S0140-6736(25)00735-4. Lancet. 2025. PMID: 40783290 Clinical Trial.
Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers.
Tapia MD, Sow SO, Naficy A, Diallo F, Haidara FC, Chaudhari A, Martellet L, Traore A, Townsend-Payne K, Borrow R, Hosken N, Smolenov I, Pisal SS, LaForce FM, Dhere RM, Kapse D, Tang Y, Alderson MR, Kulkarni PS. Tapia MD, et al. Among authors: kulkarni ps. N Engl J Med. 2021 Jun 3;384(22):2115-2123. doi: 10.1056/NEJMoa2013615. N Engl J Med. 2021. PMID: 34077644 Clinical Trial.
194 results